Interestingly, however, FIP200 ablation in BRCA1-null mouse models of breast cancer did not inhibit tumor growth by itself, but only reduced tumor growth in vivo in combination with drugs that disrupt mitochondria by inhibiting mitochondrial biogenesis and sensitizing tumor cells to mitochondrial disrupting agent-induced cell death36. This evidence concerns the gene RB1CC1 and breast carcinoma.